BRPI0407667A - metabólitos de estradiol para o tratamento de hipertensão pulmonar - Google Patents

metabólitos de estradiol para o tratamento de hipertensão pulmonar

Info

Publication number
BRPI0407667A
BRPI0407667A BRPI0407667-2A BRPI0407667A BRPI0407667A BR PI0407667 A BRPI0407667 A BR PI0407667A BR PI0407667 A BRPI0407667 A BR PI0407667A BR PI0407667 A BRPI0407667 A BR PI0407667A
Authority
BR
Brazil
Prior art keywords
estradiol
pulmonary hypertension
treatment
metabolites
hydroxy
Prior art date
Application number
BRPI0407667-2A
Other languages
English (en)
Inventor
Stevan P Tofovic
Edwin K Jackson
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of BRPI0407667A publication Critical patent/BRPI0407667A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10P—GENERIC PROCESSES OR APPARATUS FOR THE MANUFACTURE OR TREATMENT OF DEVICES COVERED BY CLASS H10
    • H10P76/00—Manufacture or treatment of masks on semiconductor bodies, e.g. by lithography or photolithography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"METABóLITOS DE ESTRADIOL PARA O TRATAMENTO DE HYPERTENSãO PULMONAR". Compreendendo métodos para o tratamento de hipertensão pulmonar e outras condições associadas com a mesma. Particularmente, os métodos incluem o tratamento de hipertensão pulmonar com metabólito do estradiol ou metabólito de estradiol associado com micropartículas ou nanopartículas biodegradáveis sozinhas ou em combinação com um outro agente terapêutico. Os metabólitos de estradiol preferidos incluem 2-metóxi estradiol, 4-metóxi estradiol, 2-hidróxi estradiol e 4-hidróxi estradiol, e/ou os derivados sintéticos e análogos dos mesmos ou os pró-medicamentos dos mesmos. As composições também podem estar na forma de uma formulação de liberação controlada.
BRPI0407667-2A 2003-02-20 2004-02-20 metabólitos de estradiol para o tratamento de hipertensão pulmonar BRPI0407667A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44811803P 2003-02-20 2003-02-20
PCT/US2004/004841 WO2004073643A2 (en) 2003-02-20 2004-02-20 Estradiol metabolites for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
BRPI0407667A true BRPI0407667A (pt) 2006-03-01

Family

ID=32908538

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407667-2A BRPI0407667A (pt) 2003-02-20 2004-02-20 metabólitos de estradiol para o tratamento de hipertensão pulmonar

Country Status (9)

Country Link
US (1) US7192941B2 (pt)
EP (1) EP1610798A4 (pt)
JP (1) JP2006518393A (pt)
KR (1) KR20050104383A (pt)
CN (1) CN100406015C (pt)
AU (1) AU2004213007A1 (pt)
BR (1) BRPI0407667A (pt)
CA (1) CA2516452A1 (pt)
WO (1) WO2004073643A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1633367A2 (en) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
KR20080086511A (ko) * 2005-12-20 2008-09-25 이카겐, 인코포레이티드 트리아릴 메탄 화합물을 이용한 치료 방법
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
CN101249071B (zh) * 2008-04-02 2010-06-16 郑州大学 2-甲氧基雌二醇静脉纳米乳剂的制备方法
CN101249070B (zh) * 2008-04-02 2010-07-21 郑州大学 2-甲氧基雌二醇静脉纳米乳剂
CN101822636A (zh) * 2010-05-24 2010-09-08 中国人民解放军军事医学科学院放射与辐射医学研究所 可注射雌三醇缓控释给药系统
CL2013003807A1 (es) * 2013-12-31 2014-07-11 Univ Santiago Chile Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol.
KR20190005708A (ko) * 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
ES2221931T3 (es) * 1994-10-28 2005-01-16 Advanced Medical Solutions Limited Hidrogeles deshidratados.
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
CN1245982C (zh) * 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
EP0964690B1 (en) * 1996-10-15 2003-07-09 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
US5874098A (en) * 1997-05-28 1999-02-23 Ivy Laboratories, Inc. Pellet implant system
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6367929B1 (en) * 1998-03-02 2002-04-09 Johnson & Johnson Vision Care, Inc. Hydrogel with internal wetting agent
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6372813B1 (en) * 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins

Also Published As

Publication number Publication date
CN100406015C (zh) 2008-07-30
US7192941B2 (en) 2007-03-20
CA2516452A1 (en) 2004-09-02
US20040209855A1 (en) 2004-10-21
JP2006518393A (ja) 2006-08-10
EP1610798A4 (en) 2007-08-08
WO2004073643A2 (en) 2004-09-02
AU2004213007A1 (en) 2004-09-02
EP1610798A2 (en) 2006-01-04
WO2004073643A3 (en) 2005-03-24
CN1764461A (zh) 2006-04-26
KR20050104383A (ko) 2005-11-02

Similar Documents

Publication Publication Date Title
BRPI0407667A (pt) metabólitos de estradiol para o tratamento de hipertensão pulmonar
BRPI0915986A2 (pt) composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0820576A2 (pt) "vírus da varíola, processo para preparar o mesmo, composição, uso de um vírus da varíola uo uma composição, e método para tratar doenças"
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
CY1109929T1 (el) Φαρμακευτικη συνθεση η οποια περιεχει φενοφιμπρατη και μεθοδος για την παρασκευη της
BRPI0817063A2 (pt) "métodos de inibição, para o tratamento de uma condição patológica, para a inibição de linfagiogênese tumoral, de inibição ou prevenção,de desorganização, para inibição de crescimento de tumor, de tratamento, de acentuação da eficácia de um agente anti-angiogênese e antagonista de alk-1
CY1115870T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για μη νοηματικη καταστολη και τη θεραπεια ασθενειας
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
NO20082067L (no) Nye pyrimidinderivater og deres anvendelse i terapi, samt anvendelse av pyrimidinderivater for fremstilling av et legemiddel for å forebygge og/eller behandle Alzheimers sykdom
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
CU20080027A7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
EP1962873A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING OR PREVENTING OXALATE-RELATED DISEASES
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
BR112013001422A2 (pt) metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.